Videos

Kirollos Hanna, PharmD, BCPS, BCOP, reviews the use of anti-CD20 monoclonal antibodies for treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, provide insight on NCCN guideline recommendations for molecular testing in CLL and discuss the prevalence of testing for cytogenetic abnormalities.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown and a urologic surgeon, discusses hypoactive sexual desire disorder and the current treatments available for this medical condition.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses contributing factors leading to health care professionals experience of an erosion of trust in the medicine supply chain.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how drug shortages are related to medicine quality issues.

Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), discusses recent survey data demonstrating 90% of physicians had experienced an erosion of trust in the US supply chain’s ability to deliver safe, quality medicines.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, addresses how pharmacists can respond to questions patients may ask them about ketamine and other psychedelic treatments.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, explains how ketamine infusions work when administered in patients’ homes and what safety precautions would be taken by providers in this setting.

Data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded treatment offering that would include psychedelic medicines.

Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.

A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.

Drs Katie Tobon and Javier Pinilla-Ibarz explore the role of prognostic molecular testing in chronic lymphocytic leukemia and comment on challenges seen with referral patients that come from community practices.

Pfizer and BioNTech are seeking an Emergency Use Authorization for their COVID-19 vaccine to include children 6 months through 4 years of age.

Stuart Staggs, senior director of strategic programs at McKesson, discussed the encouraging metrics associated with use of the Oncology Care Model (OCM) sponsored by the Centers for Medicare and Medicaid Services.

Ned Milenkovich, PharmD, JD, licensed pharmacist and principal at Much Law, PC, discusses the announcement of the Mark Cuban Cost Plus Drug Company, which will, in some cases, offer expensive medication at a drastically lower price without insurance.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.

Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.

Stacy Miller, PharmD, BCPP, the senior content management consultant at Wolters Kluwer Health, discusses clinician search data focused on mental health treatment trends and needs.

Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.

Dr Kirollos Hanna details clinical trial data on the use of zanubrutinib in treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, review challenges in CLL therapy, including cost barriers.

Pharmacists are essential team members for the education of patients with diabetes, especially around injection technique for patients using injectable medications, such as insulin.

Emily Kaine, MD, senior VP global health and manufacturing services at US Pharmacopeia (USP), discusses the work USP is engaged in to strengthen the global supply chain of quality-assured medicines and build manufacturing capabilities for new and innovative medicines.

Ashley Woodyard, a PharmD candidate at the Touro University California College of Pharmacy in Vallejo and co-author of an article in the January 2022 issue of Pharmacy Times®, discussed the article and the benefits of pharmacy technicians as vaccine administrators.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.